Braveheart Bio (BRVE) logo

Braveheart Bio (BRVE) stock

Cardiovascular therapeutics , market cap $1.7B

$20.39
+5.81%

Quality Score
1
Below Average
In its industry
#89of 273
Checks firing
3of 14
Transition
From its high
-36.3%
under its best since listing

BRVE's Quality Score fell 1 point on Fri, Nov 20, to 1. It closed away from its high of the day.

New listing, trading since Aug 6, 2026. 76 trading days so far, so 3 of the 14 chart checks wait for more history.

Follow BRVE's trial news. Pro members can get an alert when Braveheart Bio files news, and see its trials, share raises, and its CEO's filings.

Get an alert when BRVE files news on its trialsSee it live, free until Tuesday morning. No account. No card.One stock in full, free. No account.$1 for a first month of Pro. Then $39 a month. Then keep going with a free account.Then $1 for a first month of Pro.Then 7 days of Pro free, with a card.

We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.

Next1H 2027“…Phase 3 trial of HRS-1893 on top of standard of care, with topline results expected in the first half of 2027…”Trial data · SEC filing · Nov 10

Why is BRVE up?

Up 7% on Nov 11, an up day for the market: the S&P 500 rose 1%, 62% of stocks rose, and biotech stocks a median 0.9%.

  • Its Nov 10 results: net loss narrowed to $26.5M, from $59.1M a year before. It rose 7% on Nov 11.

Sources: Price history, Nov 11, 2026; Company release, Nov 10, 2026

1 more reason, free with an account →See every reason on BRVE →1 more reason why BRVE rose on Nov 11, from its filings, with the other side, the timeline, and its peers, for Pro members.

Key facts on BRVE

Key facts on BRVE
Holding it backMoves 8.1% a day with no profit behind it
Latest filing8-K, Nov 10 Reported its quarterly results

BRVE catalysts

Coming up

After its last 2 reports it closed +2.4% on average, higher 1 of 2 times.

What's next for BRVE, and how long its cash lasts

Next step the company has named

1H 2027“…Bio’s collaboration partner in Greater China, has completed enrollment in its Phase 3 trial of HRS-1893 on top of standard of care, with topline results expected in the first half of 2027.”Trial data · SEC filing · Nov 10

What it means: the first look at a trial’s main results, as the company reports them.

Lead program
HRS-1893
Another trial
LIONHEART-HCMPhase 3 · Recruiting · 210 people · main data estimated Oct 2028 · NCT07755904

1 more trial, 2 more milestones and 4 filings, for Pro members.

Cash runway Sep 30 balance sheet

$504M in cash

Fewer than four quarters of cash flow are on file.

What it means: a runway is counted only when each of the last four quarters used cash. The company's estimate is “into 2029” (8-K, Nov 10).

For Pro members: the cash used each quarter, and the math.

Dilution on the horizon

No shelf registration or at-the-market program on file in the last three years.

For Pro members: 1 raise and its amount, and the share count against a year ago.

Insiders

Director Erez Chimovits bought 1,940,000 shares on Aug 7. 7 more insider trades this year.

From Form 4: open-market buys and sales only.

For Pro members: every trade, and Travis Murdoch’s 5 filings and quotes.

Get an alert when BRVE files news on its trialsA free account. No card.Pro: $1 first month.Pro, 7 days free with a card.

See every upcoming FDA date →

FDA dates in the next 60 days

Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.

DateStockDrug

12 more FDA dates and 98 trial data dates in the next 60 days, each on the FDA calendar. Pro members see whether each company's cash lasts past its date, with an optional alert before it. See all 144 dates, ranked →See all 144 dates, ranked →Start Pro

Why BRVE scores 1

Below Averagefor quality, not price, 3 of 14 chart checks firingWhat the Quality Score means

  • +3Chart checks 3 of 14 firing right now, one point each
  • −2Volatility moves 8.1% a day with no profit or positive free cash flow over four quarters on fileA daily range of 5% or more with nothing behind it (no profit or cash flow, sales shrinking, or 10% more shares outstanding with no free cash flow): -1, or -2 from 8%.

No effect today: Long-term trend, Run-up, Size, Profit, Growth, Dilution, Cash flow, Persistence, and News.

What every line is worth, and the reason behind it, on BRVE and every other stock.Get in free →See the top 3 →Start Pro

Price, score, chart checks, and the industry rank are from a snapshot taken at 8:56 PM ET, at least 15 minutes behind. How we rank stocks.

Tested. Our top-scored stocks returned 2.2x the average stock over the next month. Reconstructed after the fact; recorded live since Sep 9, 2026. How we tested it

Alert me when BRVE's Quality Score turns up

A free account. No card.Pro: $1 first month.Pro, 7 days free with a card.

How BRVE ranks in Biotech

BRVE is #89 of 273 by Quality Score.

How BRVE ranks in Biotech
RankStockQuality Score
89Braveheart Bio (BRVE) logoBRVEBraveheart Bio1

More in Biotech

When does BRVE report earnings, and what happens after?

Expected to report Thu Mar 18, after the close (in 117 days).

What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.

What BRVE reported on Nov 10, 2026

The quarter

A loss of $0.51 a share, from $10.05.

“The increase was primarily due to clinical and manufacturing costs to support the initiation and enrollment of LIONHEART-HCM, higher personnel-related costs and a $1.0 million milestone under the Hengrui license agreement.”

The quarter that ended Sep 30, from the company's press release

The press releaseThe filing on EDGAR

Where the sales came from

BRVE's results filing gives no sales by line in a table we read.

The outlook

No outlook figures read from this release.

In the company's words

  • “The increase was primarily due to personnel-related costs, including stock-based compensation, and consultant and legal costs to support Braveheart Bio's growth and operations as a public company.”

From its results filing (SEC filing · Nov 10)

1 more sentence, for Pro members.

The numbers

Market value
$1.7B
today

No analyst estimates on Breakaway: every figure here is filed.

The whole report on BRVE: every line of its sales, every outlook beside the one it replaced, and the company's words, for Pro members.

Close after the report, last 2

-1.7%+6.5%
Sep 8Nov 10
ReportedGapReaction5
days
Nov 10, 2026After close+2.1%+6.5%-4.3%
Sep 8, 2026After close-0.9%-1.7%-9.2%

BRVE closed higher after 1 of its last 2 reports.

BRVE has 3 of 14 chart checks firing

Volume1 of 3 shown
Tight range1 of 3 shown
Buying1 of 3 shown
The other 10 checks on BRVE, and all 14 on every stock.Get in free →See the top 3 →Start Pro

BRVE RSI on Nov 20: 50.7, below its 50-day average

Not scored

RSI 50.7, MACD above signal. Not scored.

BRVE share count over time

Shares: 8.9 times the count a year ago (to Sep 30).

Shares of BRVE outstanding, as filed
Shares
outstanding
As
of
89.9MNov 6, 2026
90MSep 3, 2026
Offerings, shelves, and splits of BRVE, from its filings
From its
filings
Filed
Raised $382.5M in a sale of shares, about 22% of its market valueAug 6, 2026
Registered shares for sale (S-1)Jul 15, 2026

BRVE's officers and directors

Officers and directors with a Form 4 in the last 12 months.

See insider trades by person

About Braveheart Bio

Braveheart Bio Inc is a clinical-stage biotechnology company focused on developing therapeutics to treat hypertrophic cardiomyopathy (HCM) and other cardiovascular diseases. Its flagship product candidate, BHB-1893, is an oral small-molecule cardiac myosin inhibitor being developed for the treatment of obstructive HCM (oHCM) and non-obstructive HCM (nHCM).

San Francisco, CAbraveheart.bio

Listed on Nasdaq on Aug 6, 2026, and is 13% above its $18 offer price now. Its IPO filing and first days

Here is what Pro members see.

  • The same page for Pro members, on Microsoft

    Its Quality Score and rank, the line that drives it, and the live price.

  • The full chart

    A year of candles to start, out to the whole history, with insider trades marked and the Quality Score under the price.

  • Every line of the score

    Price action, the company, and signals, each with its points, on BRVE and every other stock.

  • FDA dates, counted down

    Each date in the company's words, its cash against the date, and an optional alert before it.

  • CEOs buying their own stock

    Every CEO buy, biggest names first. Sort, filter, save the list, and set optional alerts.

  • Congress trades

    A member's trades, newest first, each with its amount. Sort and filter the whole list.

  • 14 chart checks, read for you

    The ones firing on the stock, each in plain words, its rule a tap away.

  • Earnings, week by week

    Who reports each day, and how each stock took its last four reports.

  • The market map

    Every stock a box, colored by its Quality Score.

  • Themes, ranked live

    Each theme's stocks ranked by Quality Score, live. Here, AI chips.

  • The top 10, every day

    The ten highest Quality Scores at each close, kept day by day, week by week.

  • Optional alerts, your way

    Pick a stock, a score, a price, a filing, or a whole scan. It tells you by push or email.

  • Your watchlist, scored

    Your stocks by Quality Score, today's move, or name.

  • On your phone and your laptop

    The same account and watchlist on both, each laid out for its screen.

  • Prices refresh every 2.5 seconds during market hours.
  • Optional alerts by push, email, or the bell.
  • Add it to your Home Screen and it opens like an app.

Pro members see every line of every stock's score.

  • What would turn BRVE's score around: 3 things
  • 4 more filings explained, a plain line each
  • Real-⁠time prices, no delay

See it live, free until Tuesday morning. No account. No card.One stock in full, free. No account.$1 for a first month of Pro. Then $39 a month. Then keep going with a free account.Then $1 for a first month of Pro.Then 7 days of Pro free, with a card.

Straight AnswersStraight Answers

As of Nov 21, 2026: BRVE's Quality Score is 1 (Below Average), #89 of 273 in Biotech.

What does BRVE's Quality Score say?

BRVE scores 1 today, which Breakaway calls Below Average. It is #89 of 273 in Biotech by Quality Score, with 3 of 14 chart checks firing. Up 7% on Nov 11, an up day for the market: the S&P 500 rose 1%, 62% of stocks rose, and biotech stocks a median 0.9%. Shares: 8.9 times the count a year ago (to Sep 30). Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.

What is BRVE's Quality Score?

BRVE scores 1 today, which Breakaway calls Below Average (0 to 5). That is #89 of 273 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind BRVE's 1.

When does BRVE report earnings?

Expected to report Thu Mar 18, after the close, a date Breakaway expects from the company's usual timing; the company has not confirmed it. BRVE closed higher after 1 of its last 2 reports. Past behavior, not a forecast.

Are the prices delayed?

Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.

Only on the public pages, which run at least 15 minutes behind. Pro members see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included. The one stock you open in full is live too.

Every US stock, ranked live.

Insider and Congress trades, the chart, and the financials, in one score.

See all 3,170 stocks rankedSee all 3,170 stocks rankedStart Pro

See it live, free until Tuesday morning. No account. No card.One stock in full, free. No account.$1 for a first month of Pro. Then $39 a month. Then keep going with a free account.Then $1 for a first month of Pro.Then 7 days of Pro free, with a card.

What's next for Braveheart Bio: from its SEC filings and ClinicalTrials.gov, the company's words, the registry's dates, and arithmetic, not a forecast. Companies often miss the dates they set.

The moves after past earnings reports are past behavior, not a forecast.

The price, the score, the chart checks and readings, and the industry rank on this page are delayed at least 15 minutes.

Our top-scored stocks' record: Oct 2021 to Sep 2026, before costs. Recorded live since Sep 9, 2026.

Breakaway publishes impersonal securities research and analytical tools: one formula, the same score for everyone. It is not personalized investment advice, and nothing here is a recommendation to buy or sell any security.

Market data from a licensed vendor. The age of every quote is shown on the page.

This browser is too old to show this page right. Update it, or open this page in Safari or Chrome.